Anavex Life Sciences Corp. (Nasdaq: AVXL) will design a double-blinded, randomized, placebo-controlled Phase 2/3 study for its Alzheimer's disease treatment ANAVEX 2-73. The stock price leaped $2.06 to close at $5.30.
Anavex Life Sciences advances ANAVEX 2-73
November 18, 2015 at 16:03 PM EST
